Cinca Syndrome
Disease Details
Family Health Simplified
- Description
- CINCA syndrome (Chronic Infantile Neurological Cutaneous and Articular syndrome) is a rare autoinflammatory disorder characterized by early-onset chronic inflammation affecting the skin, joints, and central nervous system.
- Type
- CINCA syndrome, also known as Chronic Infantile Neurological, Cutaneous, and Articular syndrome, is an autoinflammatory disease. The type of genetic transmission is autosomal dominant.
- Signs And Symptoms
-
Signs and Symptoms of CINCA Syndrome (Chronic Infantile Neurological Cutaneous and Articular Syndrome):
- **Neurological**: Chronic meningitis, developmental delays, intellectual disability, seizures, and increased intracranial pressure.
- **Cutaneous**: Persistent urticarial rash, often present from birth or early infancy.
- **Articular**: Joint swelling, chronic arthritis, and deformities.
- **Systemic**: Fever, growth retardation, and hearing loss.
Nan: Not applicable to CINCA Syndrome. - Prognosis
-
CINCA syndrome (Chronic Infantile Neurological, Cutaneous, and Articular syndrome) is a rare autoinflammatory disorder also known as NOMID (Neonatal-Onset Multisystem Inflammatory Disease). The prognosis varies:
1. **Prognosis**: The prognosis for CINCA syndrome varies among individuals but is generally seen as chronic and progressive. With early diagnosis and proper medical intervention, such as the use of interleukin-1 inhibitors, many patients can see significant improvement in symptoms and quality of life. However, some may experience persistent challenges including physical disabilities, developmental delays, and organ damage.
Note: If "nan" was intended as an abbreviation or a specific term, please clarify for a more accurate response. - Onset
- CINCA Syndrome, also known as Chronic Infantile Neurological, Cutaneous, and Articular syndrome, typically has an onset in infancy, often within the first weeks to months of life.
- Prevalence
- CINCA syndrome (Chronic Infantile Neurological Cutaneous and Articular syndrome) is an extremely rare autoinflammatory disorder. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in a million individuals globally.
- Epidemiology
- Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome, also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID), is extremely rare, with only a few hundred cases reported worldwide. However, precise epidemiological data are limited due to its rarity. CINCA syndrome typically manifests shortly after birth or within the first six months of life and affects both males and females. The syndrome arises due to mutations in the NLRP3 gene, which leads to excessive inflammation.
- Intractability
- CINCA syndrome, which stands for Chronic Infantile Neurological, Cutaneous, and Articular syndrome, is generally considered an intractable disease. It is a rare genetic disorder often caused by mutations in the NLRP3 gene, leading to excessive inflammation. The symptoms can be severe and persistent, and while treatment options such as anti-inflammatory drugs and biologics can help manage symptoms and improve quality of life, there is currently no cure. Consequently, long-term medical management is often required.
- Disease Severity
- CINCA syndrome (Chronic Infantile Neurological, Cutaneous, and Articular syndrome), also known as NOMID (Neonatal-Onset Multisystem Inflammatory Disease), is a severe, chronic, and potentially life-threatening autoinflammatory disorder.
- Healthcare Professionals
- Disease Ontology ID - DOID:0090029
- Pathophysiology
- CINCA syndrome (Chronic Infantile Neurologic, Cutaneous, Articular syndrome), also known as neonatal-onset multisystem inflammatory disease (NOMID), is a rare autoinflammatory disorder. The pathophysiology involves mutations in the NLRP3 gene, which encodes the protein cryopyrin. These mutations lead to overactivation of the cryopyrin inflammasome, a component of the innate immune system. Consequently, there is excessive production of interleukin-1β (IL-1β), a pro-inflammatory cytokine. This overproduction results in chronic systemic inflammation, affecting various organs including the skin, joints, and central nervous system.
- Carrier Status
- CINCA syndrome, also known as Chronic Infantile Neurologic, Cutaneous, and Articular syndrome, is an autosomal dominant condition typically caused by mutations in the NLRP3 gene. Carrier status is not applicable (n/a) in this context, as the disease manifests in individuals who inherit one copy of the mutated gene.
- Mechanism
-
CINCA syndrome, also known as Chronic Infantile Neurological Cutaneous and Articular syndrome, is typically caused by mutations in the NLRP3 gene. This gene encodes a protein called cryopyrin, which is involved in the regulation of the immune system.
### Mechanism:
CINCA syndrome is characterized by excessive inflammation due to the overactivation of the immune system. The NLRP3 gene mutations lead to an abnormal activation of the inflammasome, a multiprotein complex that plays a crucial role in the inflammatory process. This results in increased production of pro-inflammatory cytokines like interleukin-1 beta (IL-1β).
### Molecular Mechanisms:
1. **NLRP3 Inflammasome Activation**: The mutated NLRP3 gene produces a defective cryopyrin protein that constitutively activates the inflammasome.
2. **Caspase-1 Activation**: The inflammasome activates caspase-1, an enzyme that processes precursor forms of inflammatory cytokines into their active forms.
3. **Cytokine Release**: Active caspase-1 enables the maturation and secretion of IL-1β and other pro-inflammatory cytokines, driving chronic inflammation.
4. **Systemic Inflammation**: The excessive cytokine release leads to systemic symptoms, including fever, rash, joint inflammation, and chronic meningitis, which characterize CINCA syndrome. - Treatment
-
Chronic Infantile Neurological Cutaneous and Articular (CINCA) Syndrome, also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID), is a rare autoinflammatory disease. Treatment typically involves:
1. **Interleukin-1 (IL-1) Inhibitors**: Medications such as anakinra, canakinumab, or rilonacept are commonly used to block the action of IL-1, a protein that plays a central role in inflammation.
2. **Corticosteroids**: These are sometimes used to control inflammation and symptoms in the short term.
3. **Supportive Care**: Management of symptoms such as pain, fever, and rash, along with physical therapy for joint issues.
Prompt treatment is necessary to manage symptoms and prevent complications. Always consult a healthcare provider for personalized medical advice. - Compassionate Use Treatment
-
CINCA syndrome (Chronic Infantile Neurological, Cutaneous, and Articular syndrome) is a rare genetic disorder. Treatments often focus on managing symptoms and improving quality of life. While there is no cure, some treatments have shown promise:
1. **Canakinumab (Ilaris)**: An IL-1β inhibitor approved for certain inflammatory conditions but used off-label for CINCA syndrome.
2. **Anakinra (Kineret)**: An IL-1 receptor antagonist used off-label and often considered the mainstay treatment.
3. **Rilonacept (Arcalyst)**: Another IL-1 blocking agent used experimentally.
4. **Tocilizumab (Actemra)**: An IL-6 inhibitor, sometimes used experimentally when IL-1 blockers are ineffective.
Physicians may consider compassionate use of these treatments when conventional options are insufficient. Clinical trials may also provide access to experimental therapies. - Lifestyle Recommendations
-
For CINCA syndrome (Chronic Infantile Neurological, Cutaneous, and Articular syndrome), lifestyle recommendations include:
1. **Medical Management**: Regular follow-ups with a specialist, typically a rheumatologist or immunologist, are crucial for managing symptoms and preventing complications.
2. **Medication Adherence**: Consistently taking prescribed medications, such as anti-inflammatory drugs or biologics like IL-1 inhibitors, is essential to control inflammation and other symptoms.
3. **Physical Therapy**: Engaging in regular physical therapy to maintain mobility and reduce joint stiffness can improve quality of life.
4. **Balanced Diet**: A nutritious diet that supports overall health and addresses any specific dietary needs due to medication side effects or disease complications.
5. **Hydration**: Staying well-hydrated to support overall bodily functions and possibly reduce joint discomfort.
6. **Monitoring Symptoms**: Keeping a daily log of symptoms to track disease progression and inform healthcare providers can help in adjusting treatment plans.
7. **Stress Management**: Techniques such as mindfulness, meditation, or counseling can help manage stress, which may exacerbate symptoms.
8. **Environmental Adjustments**: Making modifications at home to facilitate movement and reduce falls, such as installing grab bars or using assistive devices.
9. **Support Networks**: Engaging with patient support groups or finding others who understand the condition can offer emotional and practical support.
10. **Education**: Staying informed about the latest research and treatments for CINCA syndrome to make empowered decisions about health care. - Medication
-
Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome, also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID), is a rare autoinflammatory disorder. Treatment often includes medications that target the interleukin-1 (IL-1) pathway, as this cytokine plays a key role in the inflammatory process associated with the disease.
Common medications include:
1. Anakinra: An IL-1 receptor antagonist that helps reduce inflammation and control disease symptoms.
2. Canakinumab: A monoclonal antibody targeting IL-1β, used to reduce systemic inflammation.
3. Rilonacept: Another IL-1 inhibitor that binds to and neutralizes IL-1, reducing its activity.
These treatments aim to manage symptoms, prevent disease progression, and improve quality of life. Therapy should be tailored to the individual patient's needs, and regular monitoring by a healthcare professional is essential. - Repurposable Drugs
-
Chronic infantile neurologic, cutaneous, and articular (CINCA) syndrome, also known as Neonatal-onset multisystem inflammatory disease (NOMID), is a rare auto-inflammatory disorder. Information on repurposable drugs for CINCA syndrome includes:
1. **Anakinra (Kineret)**: An interleukin-1 (IL-1) receptor antagonist commonly used in rheumatoid arthritis that has shown effectiveness in controlling symptoms of CINCA syndrome.
2. **Canakinumab (Ilaris)**: Another IL-1 beta inhibitor, indicated for several auto-inflammatory diseases, including CINCA syndrome.
3. **Rilonacept (Arcalyst)**: An IL-1 trap that can also be considered for management.
These drugs help control the excessive inflammatory response characteristic of CINCA syndrome. Always consult with a healthcare provider for the specific management of the condition. - Metabolites
- Metabolites specifically associated with Chronic Infantile Neurological, Cutaneous, and Articular (CINCA) syndrome are not well-defined in current medical literature. This syndrome, also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID), primarily involves persistent inflammation impacting multiple systems in the body. However, treatment often involves checking markers like C-reactive protein (CRP), amyloid A, and interleukin-6 (IL-6) to monitor inflammation levels. For detailed and personalized metabolite information, further diagnostic and clinical evaluation would be essential.
- Nutraceuticals
- There are currently no established nutraceutical treatments specifically for CINCA syndrome (Chronic Infantile Neurological, Cutaneous, and Articular syndrome), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Management typically involves anti-inflammatory medications like interleukin-1 inhibitors. Always consult healthcare professionals for appropriate treatment options.
- Peptides
- CINCA syndrome, also known as Chronic Infantile Neurological, Cutaneous, and Articular syndrome, may benefit from treatments involving peptides, such as IL-1 inhibitors like anakinra. These inhibitors help manage inflammation by blocking the interleukin-1 receptor. As for nanotechnology (nan), research is ongoing to explore its potential in delivering drugs more effectively, possibly enhancing treatments for inflammatory conditions like CINCA syndrome.